Get this delivered to your inbox, and more info about our products and services.
This AI-powered health tech stock is undervalued and poised for big gains, says Mizuho
The bank initiated the stock with an outperform rating.
14 words~1 min read
Related reading
AI tailwinds will drive gains for this software stock after a decline to start…
The bank upgraded shares to outperform from neutral.
Buy this digital health stock that's 'too compelling to ignore', says Raymond…
The bank upgraded the digital platform for medical professionals to a strong buy from outperform.
We're buying more of this leading AI stock on this year's undeserved pullback
The tech giant was on the shopping list we shared on Thursday.
Wall Street's top stock picks for 2026: Mizuho’s under-the-radar name that…
Based on its 12-month price target, Mizuho sees shares of Vaxcyte soaring almost 300% from current levels.
We're buying more of this megacap AI stock as the market heads for a lower open
This AI stock has a more visible path to victory than its hyperscaler peers.
This AI derivative play is one of the hottest stocks of the year. Goldman sees…
The bank believes gave a boost to the company following its earnings report that delivered strong guidance for 2026.